(Q33821160)

29 July 2017

1 reference

title

Cladribine tablets: in relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

29 July 2017

main subject

0 references

2

Greg L Plosker

1 reference

29 July 2017

Victoria J Muir

1

1 reference

29 July 2017

publication date

1 March 2011

1 reference

29 July 2017

1 reference

29 July 2017

volume

25

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

239-249

1 reference

Diagnosis and treatment of multiple sclerosis

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Oral disease-modifying treatments for multiple sclerosis: the story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Cladribine: a review of its use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Impact of cladribine on soluble adhesion molecules in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Characterisation of an inclusion complex between cladribine and 2-hydroxypropyl-beta-cyclodextrin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

The clinical pharmacokinetics of cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Freedom from disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204740-000000000-00000

Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis

21 January 2018

1 reference

12 December 2020

Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.

1 reference

12 December 2020

Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

1 reference

12 December 2020

Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine

1 reference

12 December 2020

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

1 reference

12 December 2020

Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells

1 reference

12 December 2020

10.2165/11204740-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1043557278

0 references

1 reference